Oncodesign Precision Medicine Société anonyme (EPA:ALOPM)

Market Cap	6.14M
Revenue (ttm)	1.64M
Net Income (ttm)	-7.21M
Shares Out	18.17M
EPS (ttm)	-0.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,389
Average Volume	7,311
Open	0.3200
Previous Close	0.3200
Day's Range	0.3100 - 0.3380
52-Week Range	0.3110 - 1.3800
Beta	-0.56
RSI	43.32
Earnings Date	Jun 25, 2025

About EPA:ALOPM

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s pipeline includes OPM-101, a potentially inhibitor of the RIPK2 target, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; OPM-102, a novel inhibitor that is in preclinical studies for the treatment of cancer; and OPM-201, a potential LRRK2 inhibitor, which is in Phase 1 clinical trial for the treatment of Parkinson’s disease. It is also developing drugs for the treatment of pancr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 18
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALOPM

Financial Performance

In 2024, EPA:ALOPM's revenue was 1.64 million, a decrease of -6.02% compared to the previous year's 1.74 million. Losses were -7.21 million, -10.89% less than in 2023.